Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LNF1901 in advanced malignant tumors
NCT06226363Phase 1Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
Phase 1, open-label, single-arm trial of LNF1901 in cancer, sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Incidence of dose limiting toxicities at 21 days and Incidence of adverse events. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
LNF1901
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06226363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226363.